Results from a registry of patients with Ankylosing Spondylitis attending The North Western Rheumatology Unit
Orla Reynolds, Maria Lynch, Bernie McGowan, Bryan Whelan, Carmel Silke
The North Western Rheumatology Unit, Our Lady’s Hospital, Manorhamilton, Co Leitrim
Ankylosing spondylitis (AS) is a complex, debilitating disease that is insidious in onset, progressing to radiological sacroiliitis over many years1.
In collaboration with the National Ankylosing spondylitis Registry of Ireland (ASRI) The NWRU commenced the collection and recording of information pertaining to the management of patients with a diagnosis of Ankylosing spondylitis (AS).
The database is a web-based questionnaire, which contains sections on demographic data, personal and family history, systemic and musculoskeletal examination, laboratory results, co-morbidities along with pharmacological management. Since June 2014, relevant information on 54 patients attending The North Western Rheumatology Unit has been included in the registry. This study provides an overview of some of the descriptive information and patient characteristics of the initial cohort.
The registry contains information on 54 patients, 51 males [94%]; mean age 49 ± 12.6 years. Mean disease duration of the cohort was 11.9 ± 9.9 years, and mean duration of symptoms 22.9 ± 12.4 years. HLA-B27 positivity was detected in 83.3% of patients. Manifestations of extraarticular involvement were uveitis (37%), psoriasis (11%), dactylitis (11%) and inflammatory bowel disease (3.7%). In 28 (51.8%) of the patients, the BASDAI score was ?4 and in 30(55%) of patients the BASFI was ?4. Of the 50(93%) patients prescribed biologic therapies, 39% were using adalimumab, 37% were prescribed Etanercept, a further 11% were taking infliximab and 3.7% and 1.9% were being treated with Golimumab and Certolizumab respectively. In total 15 patients (27.8) had a diagnosis of hypertension, 20% had hyperlipidaemia and a further 11%, 7.4% and 13% had a diagnosis of diabetes, peptic ulcer disease and depression respectively.
The ASRI gives information on the clinical and demographic profiles of patients, along with information on quality of life measurements and disease activity scores.